Pralsetinib is a highly potent and selective RET inhibitor for patients with thyroid cancer with RET alterations. Oncogenic changes in RET are important therapeutic targets for thyroid cancer, and we aimed to evaluate the safety and anti-tumor activity of platinib.
Methods: ARROW was a Phase 1/2 open-label study in 1371 community and hospital settings in n> countries, recruiting 18 or older patients with Patients with RETmutated locally advanced or metastatic solid tumors, including RETmutated medullary thyroid carcinoma and RETfusion-positive thyroid cancer, and an Eastern Cooperative Oncology Group performance status of 0-2 (later restricted to 0-1 in a protocol amendment). For acceptance400 mgThe primary endpoint of Phase 2 was overall response rate and safety. Tumor response was evaluated in patients with RETmutated medullary thyroid cancer who had previously received capozantinib or vandetanib, or both, or who were ineligible for standard therapy, and in patients with previously treated RETfusion-positive thyroid cancer; safety was assessed in all patients with RETaltered thyroid cancer. This ongoing study is registered with clinicaltrials.govNCT03037385At the time of the interim analysis, enrollment of patients with RETfusion-positive thyroid cancer was still ongoing.
Survey results:in20173month17day to2020year5month227month11 in 2019(Recruitment cutoff for efficacy analysis)The overall response rate in patients with untreated RETmutant medullary thyroid carcinoma was 21of 15(71 %) (95% CI 48-89), The overall response rate in patients who previously received cabozantinib or vandetinib or both was 55of 33cases(60) (95% CI 46-73 ), and 8of 9cases(89) (95% CI 52-100). RET altered thyroid gland registered before 2020year5month22 day Among cancer patients, the common (≥10%) grade 3 and above treatment-related adverse events were hypertension(142 24names[17%]), neutropenia(19names[13%]), lymphopenia disease (17 patients [12%]) and anemia (14 patients [10%]). 21patients(15%) reported serious treatment-related adverse events, the most common of which (≥2%)is pneumonia(5patients[4%]). Five patients[4%]discontinued due to treatment-related events. One (1%) patient died from a treatment-related adverse event. Platinib is a new, well-tolerated and effective once-daily oral treatment option for patients with RET altered thyroid cancer. This medicine also has an overseas version. The retail price of Lucius Pharmaceuticals in Laos is more than 1,000 yuan per 100mg, 120 tablets, 4. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.
xa0
.jpeg)
